© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
February 13, 2020
There are 5 available EGFR TKIs for the treatment of patients with EGFR-mutant lung cancers: gefitinib (Iressa), erlotinib (Tarceva), afatinib (Gilotrif), dacomitinib (Vizimpro), and osimertinib.
February 11, 2020
Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer.